PierianDx, Biodesix partner on lung cancer diagnostics

2019 09 05 21 14 7857 Heart Pulmonary Trunk 400

PierianDx and Biodesix announced that they will be partnering in the development of lung cancer diagnostics based on next-generation sequencing (NGS) technology.

PierianDx will provide its interpretation technology platform for use with Biodesix's newly launched GeneStrat NGS genomic test, a blood-based tumor profiling test that detects mutations -- including EGFR, ALK, and KRAS -- in patients with non-small cell lung cancer (NSCLC).

The GeneStrat NGS test is a key part of the IQLung platform that aims to measure tumor-specific mutations and patient immune profiles with results in 72 hours.

Page 1 of 4
Next Page